Table 2 Distribution of clinical and genomic risk categories by histology.

From: The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study

 

ILC (n = 1497)

IDC (n = 5902)

P Value

Concordant risk, n (%)

797 (53.2%)

3715 (62.9%)

 

 Clinical low/Genomic low

552 (36.9%)

2305 (39.1%)

 

 Clinical high/Genomic high

245 (16.4%)

1410 (23.9%)

 

Discordant risk, n (%)

700 (46.8%)

2187 (37.1%)

<0.0011

 Clinical low/Genomic high

167 (11.2%)

1057 (17.9%)

 

 Clinical high/Genomic low

533 (35.6%)

1130 (19.2%)

<0.0012

  1. Patients with ILC were significantly more likely to have discordance between clinical and genomic risk; among those with discordant risk, individuals with ILC were significantly more likely to have clinical high/genomic low-risk status.
  2. 1P value from chi-square tests for discordant risk vs. concordant risk.
  3. 2P value from chi-square tests for clinical high/genomic low status vs. clinical low/genomic high status.
  4. ILC invasive lobular carcinoma, IDC invasive ductal carcinoma.
Back to article page